Pfizer has asked the U.S. Food and Drug Administration (FDA) to expand the emergency use authorization of its COVID-19 vaccine to include kids ages 12 to 15.
In an announcement on Friday (April 9), the company said its request for expanded authorization is based on data from its Phase 3 trial in adolescents, which found the vaccine was 100% effective in this age group.
"Pending regulatory decision, our hope is to make this vaccine available to the 12-15-year-old age group before the start of the 2021 school year," the company said in a post on Twitter.
The vaccine is currently authorized for emergency use in people ages 16 and older, and Pfizer's request asked the FDA to amend this authorization to allow the vaccine in adolescents. The company said it plans to make similar requests to regulatory authorities worldwide in the coming days.
Originally published on Live Science.
Live Science newsletter
Stay up to date on the latest science news by signing up for our Essentials newsletter.
Rachael is a Live Science contributor, and was a former channel editor and senior writer for Live Science between 2010 and 2022. She has a master's degree in journalism from New York University's Science, Health and Environmental Reporting Program. She also holds a B.S. in molecular biology and an M.S. in biology from the University of California, San Diego. Her work has appeared in Scienceline, The Washington Post and Scientific American.